Cost–utility of nelarabine for the first‐line treatment of newly diagnosed pediatric T‐cell acute lymphoblastic leukemia in Canada
Incorporating nelarabine into aBFM was cost-effective across different scenarios and assumptions. These results support its funding by public and private payers.
Authors
- Alexandra Moskalewicz (ORCID: https://orcid.org/0000-0003-2715-1135)
- Elizabeth Bond
- Sumit Gupta (ORCID: https://orcid.org/0000-0003-1334-3670)
- Paul James Gibson (ORCID: https://orcid.org/0000-0002-6422-8181)
- Petros Pechlivanoglou (ORCID: https://orcid.org/0000-0001-5090-7936)
- Roaa Shoukry
- Nicole Bradley
- M. Sala
Institutions
- Pediatric Oncology Group (CA)
- University of Toronto (CA)
- Hospital for Sick Children (CA)
- McMaster Children's Hospital (CA)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2024-10-20
- DOI
- https://doi.org/10.1002/pbc.31393
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pediatric Oncology Group of Ontario